#elispot

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global ELISpot and FluoroSpot Assay Market- (By Product (Assay Kits (Assay Kits by Technique(ELISpot Assay Kits, FluroSpot Assay Kits), Assay Kits by Utility (Diagnostic Kits, Research Kits), Assay Kits by Analyte (T-cell-based kits, B-cell-based kits, Other analytic kits), Analyzers, Ancillary products), By Application (Diagnostic Applications (Infectious Diseases, Transplants), Research Applications (Vaccine Development, Clinical Trials, Cancer Research)), By End-User (Hospitals & Clinical Labs, Research Institutes, Biopharmaceutical Companies and CROs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global ELISpot and FluoroSpot Assay Market is valued at US$ 276.18 Mn in 2022, and it is expected to reach US$ 512.39 Mn by 2031, with a CAGR of 7.2% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2000

The increasing prevalence of chronic conditions, including cancer and autoimmune disorders, serves as a major catalyst for the growth of the Enzyme-Linked Immunospot (ELISPOT) and Fluorospot assay market. These diagnostic platforms play a critical role in the early detection of disease, monitoring disease progression, and evaluating the effectiveness of therapeutic interventions. Despite their clinical utility, the National Cancer Institute has advised against the use of ELISPOT assays for monitoring immune responses to cancer antigens in clinical therapeutic trials, citing limitations in their application for this purpose.

Concurrently, the rising incidence of infectious diseases such as Human Immunodeficiency Virus (HIV) and tuberculosis is further driving demand for these assays. ELISPOT and Fluorospot technologies provide valuable insights into immune responses and disease-specific biomarkers, making them indispensable tools in both clinical research and healthcare settings. Their ability to deliver precise immunological data continues to support their expanding role in diagnostic and therapeutic evaluation.

List of Prominent Players in the ELISpot and FluoroSpot Assay Market:

Oxford Immunotec (UK)

Cellular Technology Limited (US)

Mabtech (Sweden)

Becton Dickinson and Company (US)

Abcam plc. (UK) 

Bio-Techne. (US)

Mikrogen Diagnostik (Germany)

Autoimmun Diagnostika GmbH (Germany)

U-CyTech (Netherlands)

Medix Biochemica (Finland)

Merck KGaA (Germany)

Bio-Sys GmbH (Germany)

Anogen-Yes Biotech Laboratories Ltd (Canada)

Abnova Corporation (Taiwan)

Biorbyt Ltd (UK),

Tokyo Chemical Industry Co., Ltd. (Japan),

MP BIOMEDICALS. (US),

BOC Sciences. (US),

ZenBio, Inc (US)

Jackson ImmunoResearch Inc (US),

Krishgen Biosystems. (India)

NATIONAL ANALYTICAL CORPORATION (India),

STEMCELL Technologies Inc. (Canada),

SERVA Electrophoresis GmbH (Germany),

IST Scitific LTD (England).

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics

Drivers:

Manufacturers are increasingly engaging in strategic acquisitions, partnerships, and collaborations with regional and local entities to meet the rising demand for ELISpot and FluoroSpot assay diagnostics in emerging markets. For example, in February 2022, @Siemens Healthineers (Germany) partnered with @UNICEF (United States) to enhance healthcare infrastructure in Sub-Saharan Africa by expanding access to diagnostic services and treatment. Furthermore, regulatory environments in the Asia Pacific region are generally more conducive to business expansion compared to the more stringent frameworks in North America and Europe. As competition intensifies in mature markets, manufacturers are progressively shifting their focus toward growth opportunities in Asia Pacific and Latin America.

Challenges:

Intracellular cytokine staining (ICS) combined with flow cytometry continues to be the most widely used method for evaluating cytokine co-expression cells, posing a substantial competitive challenge for FluoroSpot assays. Despite FluoroSpot’s higher sensitivity, ICS is often preferred due to its reliable performance in fluorescent signal detection—an area where FluoroSpot may encounter difficulties due to signal overlap between different fluorescent dyes. In response to this challenge, companies are investing in advanced detection technologies. For instance, @Mabtech AB has introduced the IRIS analyzer, which incorporates RawSpot technology to improve the accuracy of spot detection.

Regional Trends:

North America is expected to maintain its leadership position in the ELISpot and FluoroSpot assay market over the forecast period. This dominance is largely attributed to the high prevalence of cancer and infectious diseases in the region. According to the American Cancer Society’s Cancer Statistics 2022, an estimated 1.92 million new cancer cases were projected in the United States in 2022, including those involving breast cancer, leukemia, and lymphoma. Additionally, a study published by the American Academy of Pediatrics in March 2022 reported that more than one million individuals in the U.S. are living with chronic hepatitis B infections, which can lead to severe conditions such as liver cancer. The growing disease burden is expected to drive increased demand for vaccines and support the widespread adoption of ELISpot assays in infectious disease research.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2000

Recent Developments:

In Mar 2023, The T-Cell Select reagent kit from Oxford Immunotec, which is designed for in vitro diagnostic (IVD) use by accredited laboratories using the T-SPOT.TB test workflow, has received approval from the U.S. Food and Drug Administration (FDA) for the use of two additional cell isolation tools.

In Mar 2022, Medix Biochemica launched a new brand to show how its recent acquisitions have made its services more exciting and how committed it is to the in vitro diagnostics (IVD) business. Medix Biochemica became the best IVD raw materials seller because of how quickly it grew.

Segmentation of ELISpot and FluoroSpot Assay Market-

By Product-

Assay Kits

Assay Kits by Technique

ELISpot Assay Kits

FluroSpot Assay Kits

Assay Kits by Utility

Diagnostic Kits

Research Kits

Assay Kits by Analyte

T-cell-based kits

B-cell-based kits

Other analytic kits

Analyzers

Ancillary products

By Application-

Diagnostic Applications

Infectious Diseases

Transplants

Research Applications

Vaccine Development

Clinical Trials

Cancer Research

By End-User-

Hospitals & Clinical Labs

Research Institutes

Biopharmaceutical Companies and CROs

By Region-

North America-

The US

Canada

Mexico

Europe-

Germany

The UK

France

Italy

Spain

Rest of Europe

Asia-Pacific-

China

Japan

India

South Korea

Southeast Asia

Rest of Asia Pacific

Latin America-

Brazil

Argentina

Rest of Latin America

 Middle East & Africa-

GCC Countries

South Africa

Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/elispot-and-fluorospot-assay-market/2000

About Us:

Difference Between ELISPOT and ELISA

October 18, 2022 Posted by Axispharm

With the wide application of ELISA technology in the medical and biological fields, new breakthroughs have been made in the detection of various cytokines and antibodies in vitro. When studying the mechanism of immune response, enzyme-linked immunosorbent assay (ELISA) was used to detect free cytokines (CK) or antibodies in body fluids. Metabolized or combined with target organs, but cannot accurately reflect the level of antibodies and CK in vivo. In the 1980s, based on the basic principle of ELISA technology, researchers established a solid-phase enzyme-linked immunospot technique (ELISPOT) for detecting specific antibody-secreting cells and CK-secreting cells in vitro.

Main difference between ELISPOT and ELISA:

The ELISPOT method is derived from ELISA and breaks through the traditional ELISA method. It is an extension and new development of quantitative ELISA technology. Both detect cytokines or other soluble proteins produced by cells, and their biggest differences are:

1. ELISA measures the absorbance on a microplate reader through a color reaction, and compares it with the standard curve to obtain a quantitative total amount of soluble protein.

2. ELISPOT shows clearly distinguishable spots on the corresponding positions where the soluble protein is secreted by cells through the color reaction. The spots can be manually counted directly under the microscope or counted by the ELISPOT analysis system. One spot represents one spot. Active cells to calculate the frequency of cells secreting the protein or cytokine. (Some studies measure not only the amount of cytokine produced, but also the frequency of cells secreting the cytokine)

3. Because it is a single-cell level detection, ELISPOT is more sensitive than ELISA and limiting dilution methods, and can detect 1 cell secreting this protein from 200,000-300,000 cells.

4. The capture antibody is a high-affinity, high-specificity, low-endotoxin monoclonal antibody produced by Swedish high-tech biological company MABTECH, BD, R&D. When researchers activate cells with stimulators, they will not affect the secretion of cytokines by activated cells.

Detection principle

Cells are stimulated to locally produce cytokines, which are captured by specific monoclonal antibodies. After cell dissociation, the captured cytokines bind to biotin-labeled secondary antibodies, which in turn bind to alkaline phosphatase-labeled avidin. After incubation with BCIP/NBT substrate, “purple” spots appeared on the PVDF plate, indicating that the cells produced cytokines, and the results were obtained after the spots were analyzed by the ELISPOT enzyme-linked spot analysis system.

Application field

Prediction of rejection in transplantation, vaccine development, Th1/Th2 analysis, autoimmune disease research, tumor research, allergic disease research, infectious disease research, epitope mapping analysis, screening of compounds and drug immunological responses, etc.